Login to Your Account

Bari Interesting: Incyte, Lilly JAK Up Phase III Program

By Randy Osborne
Staff Writer

Wednesday, November 14, 2012
The recent approval of Pfizer Inc.'s Janus kinase inhibitor tofacitinib, branded Xeljanz, for moderate to severe rheumatoid arthritis has investors salivating over the prospects for baricitinib, the drug in the same class for the same indication from Incyte Corp. and partner Eli Lilly and Co., entering Phase III trials.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription